Office Action Analysis — App 19562541 (public record)

Candidate arguments for counsel, ranked strongest-first. Each names the limitation it hangs on, the argument for the record with pin-cites, the MPEP frame, and what the examiner is likely to say back. These are brainstorming inputs for counsel to evaluate — not a drafted response.

1. [Conclusory rationale]: Conclusory motivation to combine / bare 'predictable results' rationale

Claims addressed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29

Limitation hook: wherein the porous solid carrier comprises a mesoporous silica or an amorphous silica, wherein the porous solid carrier has at least one of [pore volume / surface area / pore diameter]

The examiner's stated reason to import Nowak's carrier properties into Friedman is that it 'would have yielded no more than the predictable results, e.g., enhanced properties of the composition obtained by using silica.' Counsel may weigh whether this is the kind of articulated reasoning with a rational underpinning that MPEP § 2143.01 requires, or a bare conclusion that the outcome would be 'predictable.' The office action does not appear to explain WHY a formulator starting from Friedman would select Nowak's specific surface-area and pore-volume windows (as opposed to any of the many silicas Friedman itself lists) to achieve a particular, articulated benefit. Under KSR/MPEP § 2143 the record must supply factual findings supporting a specific rationale, not a generalized assertion of predictability.

Supporting evidence:

• Office action: 'It would have been obvious to further define porous silica of Friedman with properties of Nowak's silica and such properties of silica would have yielded no more than the predictable results, e.g., enhanced properties of the composition obtained by using silica.'
• Office action: 'one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention ... especially in the absence of evidence to the contrary.'

Doctrine: MPEP § 2143.01 — articulated reasoning with rational underpinning; MPEP § 2143 (KSR rationales require factual findings); see also MPEP § 2145

Examiner's likely response / risk: The examiner may respond that both references address the same problem (solubility/bioavailability of poorly soluble cannabinoids) and that selecting known silica properties is a design choice yielding predictable results (MPEP § 2143(A)/(D)). Counsel should be prepared to tie the challenge to the specific unexplained selection of Nowak's property windows rather than the combination in the abstract.

2. [Conclusory rationale]: Conclusory simple-substitution for propylene glycol monocaprylate (mono vs. di)

Claims addressed: 1, 24

Limitation hook: the lipophilic material comprises ... propylene glycol monocaprylate

The office action concedes 'Friedman does not expressly teach propylene glycol monocaprylate' and bridges the gap by asserting that because Friedman teaches propylene glycol dicaprylate/dicaprate (Miglyol 840), 'selecting propylene glycol monocaprylate would be obvious variation from the standpoint of the ordinary artisan.' Under the simple-substitution rationale (MPEP § 2143(B)) the substitute must be a known equivalent and the substitution must yield predictable results, which requires an articulated factual basis; a monoester and a diester differ structurally and functionally (analysis), so counsel may weigh whether the examiner has articulated why they are art-recognized equivalents for this function. The office action does not appear to supply a finding that a formulator would have expected the monocaprylate to perform the same solubilization role as the dicaprylate/dicaprate.

Supporting evidence:

• Office action: 'Although Friedman does not expressly teach propylene glycol monocaprylate of instant claims 1 and 24, Friedman teaches equivalent emulsifiers such as propylene glycol dicaprylate/dicaprate (Miglyol® 840) ... and thus, selecting propylene glycol monocaprylate would be obvious variation from the standpoint of the ordinary artisan'
• Claim 24: 'the lipophilic material comprises propylene glycol monocaprylate'

Doctrine: MPEP § 2143(B) — simple substitution of a known equivalent for predictable results requires articulated findings; MPEP § 2143.01

Examiner's likely response / risk: The examiner may cite general formulation knowledge that mono/di propylene glycol caprylate esters are interchangeable solubilizers and reassert obvious variation. Note that claim 1 recites the lipophilic material in the alternative ('or combinations thereof'), so this point is dispositive only for claim 24 and the monocaprylate branch of claim 1; the glyceride branches would remain to be addressed. Verify Friedman's actual excipient list since it was not grounded.

3. [Improper hindsight]: Improper hindsight — porosity finding drawn from applicant's own specification

Claims addressed: 11, 12, 13

Limitation hook: the porous solid carrier has a porosity of about 60% to about 99% (claim 11); about 60% to about 75% (claim 12); surface area about 250 m²/g to about 375 m²/g and porosity about 60% to about 75% (claim 13)

For the porosity limitations of claims 11-13 the office action concedes 'the applied art alone or in combination does not expressly teach numerical numbers of porosity' and then supports the finding by stating the art teaches 'the same highly porous silicate material ... as disclosed in the instant application (see [0009]).' Counsel may weigh whether anchoring the porosity finding to the applicant's own specification is impermissible hindsight reconstruction under MPEP § 2142/§ 2145, which forbids using the applicant's disclosure as a roadmap. The examiner supplements this with Stroppolo as evidence of 60-95% porosity, but the reasoning that ties the claimed porosity to the prior art appears to originate in the instant application rather than in the cited art itself. This is grounded in the office action's own language and does not depend on the content of the unretrieved references.

Supporting evidence:

• Office action: 'the applied art alone or in combination does not expressly teach numerical numbers of porosity of solid carrier of instant claims 11-13, such properties would be obvious from the silicate material of the applied art because the Friedman/Nowak teaches the same highly porous silicate material (e.g., Neusilin US2 and Syloid® XDP) as disclosed in the instant application (see [0009])'
• Office action: 'as evidenced by Stroppolo et al. (US2017/0049806A1), such silicate materials have high porosity of 60-95% (e.g., [0018]-[0020] of Stroppolo)'

Doctrine: MPEP § 2142 / § 2145 — impermissible hindsight; the motivation must come from the prior art or knowledge in the art, not the applicant's disclosure

Examiner's likely response / risk: The examiner may reframe the point as inherency — that the named commercial silicas (Neusilin US2, Syloid XDP) inherently possess the claimed porosity — supported by Stroppolo. Counsel should be ready to test whether Stroppolo's 60-95% is necessarily present in the specific grades relied on. Because Stroppolo, Friedman, and Nowak were not grounded, verify their actual porosity teachings.

4. [Mischaracterized reference]: Cited Nowak carrier values do not overlap several claimed pore-volume/surface-area ranges (examiner's own numbers)

Claims addressed: 3, 4, 9, 10

Limitation hook: average pore volume of about 2 mL/g to about 2.5 mL/g (claims 3, 10); average surface area of about 375 m²/g to about 600 m²/g (claim 4); average surface area of about 400 m²/g to about 600 m²/g and average pore volume of about 0.5 mL/g to about 1 mL/g (claim 9)

This argument takes the examiner's own characterization of Nowak as given and does not depend on any teaching beyond what the office action itself recites. The office action states Nowak's bead has 'a specific surface area of 300-340m²/g' and 'a pore volume of 1.2-1.7 mL/g,' yet asserts those values 'overlap' claimed ranges they do not touch — 1.2-1.7 mL/g does not overlap the 2 mL/g to 2.5 mL/g range of claims 3 and 10, and does not overlap the 0.5 mL/g to 1 mL/g range of claim 9; likewise 300-340 m²/g does not reach the 375-600 m²/g surface area of claim 4 or the 400-600 m²/g of claim 9 (analysis). Under MPEP § 2144.05 the overlapping/close-range rationale requires that the cited range actually overlap or lie close to the claimed range, so for these dependent claims the prima facie case appears unsupported on the examiner's own figures. Counsel may weigh pressing this as an arithmetic gap in the § 103 rationale rather than as a factual dispute about the reference.

Supporting evidence:

• Office action: 'the bead has a specific surface area of 300-340m²/g (e.g., Table 2 – [0086]) which is within the range of ... about 375 to about 600 m²g of instant claims 4 and 10'
• Office action: 'a pore volume of 1.2-1.7 mL/g which is within the range of about 0.5mL/g to about 2.5mL/g of instant claim 1 or ... about 2mL/g to about 2.5m/g of instant claim 3 or about 2mL/g to about 2.5m/g of instant claim 10'
• Claim 9: 'average surface area of about 400 m²/g to about 600 m²/g and an average pore volume of about 0.5 mL/g to about 1 mL/g'

Doctrine: MPEP § 2144.05 — overlapping/close range obviousness requires an actual overlap or proximity; see also MPEP § 2143.01 (articulated reasoning)

Examiner's likely response / risk: The examiner may point to the Sipernat brochure (~500 m²/g) or Friedman for higher surface areas to cover claim 4/9 surface-area, and may recharacterize the pore-volume relationship. Because none of the cited references were retrieved/grounded, counsel should independently obtain and confirm the actual Nowak, Friedman, and Sipernat disclosures before finalizing this distinction. Avoid characterizing the invention narrowly around a single carrier value in a way that could later be read as a scope disclaimer.

5. [Mischaracterized reference]: Friedman's cited CBD range (0.01-20%) does not overlap the 25-35% claimed amount

Claims addressed: 16, 25

Limitation hook: cannabidiol present in an amount ranging from about 25% to about 35% by weight based on the total weight of the drug-containing particle

Taking the examiner's own characterization of Friedman as given, the office action recites Friedman's cannabidiol amount as 'about 0.01 to about 20%' and then asserts this 'overlaps ... about 25% - about 35% of instant claims 16 and 25' — but 0.01-20% and 25-35% do not overlap and are separated by a gap (analysis). For claim 15 (20-35%) the only contact is at the 20% endpoint. Under MPEP § 2144.05 a non-overlapping, non-adjacent range does not, on its face, establish the overlapping-range presumption, so counsel may weigh whether the prima facie case for these claims fails on the examiner's own figures. This is a logic/arithmetic point that does not require disputing what Friedman actually teaches.

Supporting evidence:

• Office action: 'cannabidiol (CBD) or THC ... in an amount of about 0.01 to about 20% (e.g., [0046]) that overlaps the range of about 15% to about 40% of instant claim 1, about 20% - about 35% of instant claim 15, or about 25% - about 35% of instant claims 16 and 25'
• Claim 16: 'cannabidiol is present in an amount ranging from about 25% to about 35% by weight'

Doctrine: MPEP § 2144.05 — overlapping/close range obviousness; the cited range must overlap or be close to the claimed range

Examiner's likely response / risk: The examiner may rely on Nowak's separately cited 'about 1 to about 90% cannabinoids' to reach 25-35%, or argue the ranges are 'close' under In re Aller so the burden shifts to applicant to show criticality. Because Friedman and Nowak were not grounded, verify the actual disclosed amounts. If counsel argues criticality of the 25-35% band, be mindful that characterizing that band as critical narrows scope in the file wrapper.

6. [Mischaracterized reference]: Friedman's preferred lipophilic-material amount (2-10%) does not overlap the claimed 20-35%

Claims addressed: 1

Limitation hook: a lipophilic material at an amount ranging from about 20% to about 35% by weight based on the total weight of the drug-containing particle

The office action characterizes Friedman's emulsifier/lipophilic content as 'an amount of about 1% to about 25% or about 2 to 10%' and asserts this 'overlaps the range of about 20%-about 35%.' Taking those numbers as given, the broad 1-25% figure overlaps the claimed 20-35% only in a narrow 20-25% sliver, and Friedman's preferred 2-10% range does not overlap the claimed 20-35% at all (analysis). Counsel may weigh whether the examiner's reliance on the preferred/exemplary lower range undercuts the overlapping-range rationale for the lipophilic-material amount. As with the other range points, this argument rests on the examiner's own recited figures, not on a disputed reading of the reference.

Supporting evidence:

• Office action: 'which reads on the claimed lipophilic materials in an amount of about 1% to about 25% or about 2 to 10% (e.g., [0010] and [0065]) which overlaps the range of about 20%-about 35% of instant claim 1'
• Claim 1(c): 'a lipophilic material at an amount ranging from about 20% to about 35% by weight'

Doctrine: MPEP § 2144.05 — overlapping/close range obviousness; MPEP § 2141.02 (reference considered as a whole)

Examiner's likely response / risk: The examiner will likely rely on the broader 1-25% endpoint (which touches 20-25%) and argue the ranges are close enough to shift the burden. Confirm Friedman's actual disclosed amounts since the reference was not grounded. Note the examiner also mapped multiple named excipients (Gelucire, Labrafil) as exemplary ('such as'); do not treat any single named species as definitional.

7. [Secondary considerations]: Criticality / unexpected results of the claimed CBD loading and carrier-property windows

Claims addressed: 1, 15, 16, 25

Limitation hook: cannabidiol present at about 15% to about 40% (claim 1), about 20% to about 35% (claim 15), about 25% to about 35% (claims 16, 25) with a mesoporous/amorphous silica of the recited pore volume, surface area, or pore diameter

Because the rejection rests on the overlapping-range presumption of MPEP § 2144.05, one recognized rebuttal (MPEP § 2145) is a showing that the claimed ranges produce results a PHOSITA would not have expected — for example, that the specific high CBD loading combined with the recited carrier properties yields a non-crystalline, high-release particle (claims 17, 28) that could not have been predicted from the art's lower loadings. Counsel may weigh whether the specification and available data support an unexpected-results showing commensurate in scope with the claimed ranges. Any such showing must be evidentiary, not attorney argument, and must establish a nexus to the specifically claimed loading and carrier-property combination.

Supporting evidence:

• Office action: 'MPEP 2144.05 stating that [i]n the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists.'
• Claim 17: 'the cannabidiol is present in non-crystalline form as measured by X-ray powder diffraction'; Claim 28: 'at least 50% of the cannabidiol is released ... in 1 hour'

Doctrine: MPEP § 2145 / § 716.02 — unexpected results and criticality rebut an overlapping-range prima facie case, but require evidence and a nexus commensurate with claim scope

Examiner's likely response / risk: The examiner will require that any data be commensurate in scope with the full claimed ranges and show a difference in kind or unexpected degree; results at a single loading may be dismissed as not commensurate. A criticality argument tied to the specific ranges narrows claim scope in the file wrapper (prosecution-history estoppel) and should be framed deliberately.

Evidence needed: A § 1.132 declaration presenting comparative data showing an unexpected result (e.g., unexpectedly high CBD loading in non-crystalline form and/or dissolution performance) attributable specifically to the claimed CBD-amount and carrier-property windows, commensurate in scope with the claims.

8. [Conclusory rationale]: Provisional double-patenting CBD-increase rationale is conclusory

Claims addressed: 1, 15, 16, 25

Limitation hook: cannabidiol present in the recited higher-loading ranges (e.g., about 25% to about 35%)

For the provisional nonstatutory double-patenting rejection over copending 18/597,717, the office action identifies the distinction as the instant claims' 'high amount of CBD' and disposes of it by asserting 'it would be obvious to increase the amount of CBD in order to enhance the therapeutic effects of the composition, unless there is criticality evidence of higher amount of CBD.' Counsel may weigh whether this is an articulated, factually supported obviousness rationale or a conclusory assertion that improperly shifts the burden before a prima facie case is made. Separately, both double-patenting rejections are of the nonstatutory type; counsel should weigh the availability of a terminal disclaimer as the conventional mechanism to address them, and note that the provisional rejection cannot be finalized until the conflicting claims of 18/597,717 issue.

Supporting evidence:

• Office action (Rejection 3): 'The difference between them is that instant claims require high amount of CBD, and but it would be obvious to increase the amount of CBD in order to enhance the therapeutic effects of the composition, unless there is criticality evidence of higher amount of CBD.'
• Office action: 'This is a provisional double patenting rejection since the conflicting claims have not yet been patented.'

Doctrine: MPEP § 804 (nonstatutory double patenting; terminal disclaimer practice); MPEP § 2143.01 (articulated reasoning for the obviousness-type analysis)

Examiner's likely response / risk: The examiner may maintain that increasing an active's amount to enhance efficacy is prima facie obvious absent criticality (In re Boesch line). A terminal disclaimer resolves the nonstatutory double-patenting rejections but has patent-term and enforceability consequences (common ownership/expiration) counsel must evaluate; filing one is generally not an admission of obviousness of the § 103 rejection.

9. [Mischaracterized reference]: Verify-first — no cited reference was grounded

Claims addressed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29

Limitation hook: all limitations mapped to Friedman, Nowak, Stroppolo, and the Sipernat brochure

None of the cited references (Friedman, Nowak, Stroppolo, Sipernat brochure) were retrieved or grounded in the record provided, so their actual disclosures cannot be independently confirmed here. Before relying on any of the range/teaching distinctions above, counsel should obtain and verify the specific passages the examiner cites — in particular Friedman's actual CBD amount ([0046]) and lipophilic-material amount ([0010], [0065]), Nowak's surface-area and pore-volume tables ([0086]), and whether the named commercial silicas carry the recited properties. This posture is provisional and should be treated as a due-diligence step supporting (not replacing) the higher-ranked arguments, all of which are framed on the examiner's own recited figures.

Supporting evidence:

• Reference grounding: 'no cited references were grounded'
• Office action cites Friedman [0046], [0010], [0065] and Nowak [0086], [0061], [0017], [0070]-[0075] as the basis for the mapped amounts and properties

Doctrine: MPEP § 2141.02 — a reference must be considered in its entirety; findings must rest on what the reference actually discloses

Examiner's likely response / risk: This is a verify-first posture, not a substantive distinction; it must not be presented as a missing-element or mischaracterization conclusion until the reference text is confirmed. Once verified, any confirmed mischaracterization or missing teaching can be elevated; if the references confirm the examiner's figures, the range-overlap arguments above may need to shift to a criticality/unexpected-results footing.

Evidence needed: Retrieved copies of Friedman (US2021/0212946A1), Nowak (US2020/0046642A1), Stroppolo (US2017/0049806A1), and the Sipernat brochure to confirm the cited passages.